William Blair Issues Positive Estimate for Merus Earnings

Merus (NASDAQ:MRUS - Free Report) - William Blair increased their Q2 2025 EPS estimates for shares of Merus in a report released on Wednesday, May 7th. William Blair analyst M. Phipps now forecasts that the biotechnology company will post earnings per share of ($1.09) for the quarter, up from their previous forecast of ($1.27). William Blair has a "Outperform" rating on the stock. The consensus estimate for Merus' current full-year earnings is ($3.85) per share. William Blair also issued estimates for Merus' Q3 2025 earnings at ($1.07) EPS, Q4 2025 earnings at ($1.02) EPS, FY2025 earnings at ($4.56) EPS, Q1 2026 earnings at ($1.08) EPS, Q2 2026 earnings at ($0.98) EPS, Q3 2026 earnings at ($0.92) EPS, Q4 2026 earnings at ($0.92) EPS, FY2026 earnings at ($3.89) EPS, FY2027 earnings at ($3.83) EPS and FY2028 earnings at ($3.23) EPS.

A number of other brokerages have also weighed in on MRUS. Wells Fargo & Company reduced their price objective on shares of Merus from $91.00 to $89.00 and set an "overweight" rating on the stock in a report on Thursday, May 8th. Needham & Company LLC restated a "buy" rating and issued a $83.00 price objective on shares of Merus in a report on Wednesday, April 9th. Piper Sandler initiated coverage on shares of Merus in a report on Thursday, February 13th. They issued an "overweight" rating and a $84.00 price objective on the stock. Guggenheim reiterated a "buy" rating and issued a $109.00 price target on shares of Merus in a research note on Friday, March 28th. Finally, HC Wainwright reiterated a "buy" rating and issued a $85.00 price target on shares of Merus in a research note on Monday, March 3rd. One analyst has rated the stock with a sell rating, fourteen have given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $85.15.

Merus Price Performance

Shares of MRUS stock traded down $0.52 during trading hours on Monday, reaching $40.40. 655,348 shares of the stock were exchanged, compared to its average volume of 717,961. Merus has a 12-month low of $33.19 and a 12-month high of $61.61. The business's fifty day moving average is $43.43 and its two-hundred day moving average is $43.96. The firm has a market capitalization of $2.80 billion, a P/E ratio of -10.23 and a beta of 0.94.

Merus (NASDAQ:MRUS - Get Free Report) last released its earnings results on Wednesday, May 14th. The biotechnology company reported ($1.40) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.23). The company had revenue of $26.49 million for the quarter, compared to analyst estimates of $7.82 million. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%.

Institutional Investors Weigh In On Merus

Several large investors have recently modified their holdings of the company. KBC Group NV boosted its stake in Merus by 4,583.6% during the 4th quarter. KBC Group NV now owns 57,234 shares of the biotechnology company's stock worth $2,407,000 after purchasing an additional 56,012 shares during the period. State of New Jersey Common Pension Fund D increased its position in Merus by 29.0% in the 4th quarter. State of New Jersey Common Pension Fund D now owns 48,268 shares of the biotechnology company's stock valued at $2,030,000 after acquiring an additional 10,842 shares during the period. Raymond James Financial Inc. acquired a new position in Merus in the 4th quarter valued at about $347,000. Swiss National Bank raised its stake in Merus by 9.7% during the 4th quarter. Swiss National Bank now owns 93,954 shares of the biotechnology company's stock valued at $3,951,000 after acquiring an additional 8,300 shares during the last quarter. Finally, Baker BROS. Advisors LP lifted its position in Merus by 50.0% during the 4th quarter. Baker BROS. Advisors LP now owns 450,000 shares of the biotechnology company's stock worth $18,922,000 after acquiring an additional 150,000 shares during the period. 96.14% of the stock is owned by institutional investors and hedge funds.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.